Bone and tissue changes following prostaglandin therapy in neonates

Area of Science:

• Neonatal pharmacology
• Pediatric skeletal radiology
• Adverse drug reactions

Background:

• Prostaglandin infusions are used in neonates for various conditions.
• Potential adverse effects, including skeletal changes, require careful consideration.

Purpose of the Study:

• To review case reports of bone changes and tissue swelling in neonates due to prostaglandin therapy.
• To inform healthcare providers about these potential complications.

Main Methods:

• Literature search of English-language case reports using Index Medicus and bibliographic databases.
• Focus on prostaglandin-induced bone changes and tissue swelling in neonates.

Main Results:

• Prostaglandin infusion is linked to cortical bone proliferation in neonates.
• Observed skeletal changes include widened fontanelles and limb swelling, potentially lasting up to 38 weeks post-therapy.
• Elevated alkaline phosphatase (AP) levels were noted in some cases, suggesting it as a potential monitoring marker.

Conclusions:

• Healthcare professionals should be aware of prostaglandin-induced skeletal changes in neonates.
• Optimizing dosage and limiting exposure duration are recommended.
• Monitoring AP levels may aid in predicting or preventing complications.